Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - An individual patient data meta-analysis

European Neuropsychopharmacology

Volumn 24, Issue 7, 2014, Pages 1067-1077

  Mattila, Taina ^a   Wohlfarth, Tamar ^a,b   Koeter, Maarten ^b   Storosum, Jitschak ^b   van den Brink, Wim ^b   de Haan, Lieuwe ^b   Leufkens, Hubertus ^a   Denys, Damiaan ^b  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antipsychotics; Meta analysis; Region; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL EXAMINATION; DRUG EFFICACY; EMERGENCY CARE; EUROPE; HUMAN; META ANALYSIS; NORTH AMERICA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TREND STUDY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; EUROPE; HUMANS; NORTH AMERICA; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84902344623     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.02.006     Document Type: Article

References (28)

1. Bersani F.S., Capra E., Minichino A., Pannese R., Girardi N., Marini I., Delle Chiaie R., Biondi M. Factors affecting interindividual differences in clozapine response: a review and case report. Hum. Psychopharmacol. 2011, 26:177-187.
2. Bigos K.L., Bies R.R., Pollock B.G., Lowy J.J., Zhang F., Weinberger D.R. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol. Psychiatry 2011, 16:620-625.
3. Chen Y.F., Wang S.J., Khin N.A., Hung H.M., Laughren T.P. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm. Stat. 2010, 9:217-229.
4. CHMP, 2008. Reflection Paper on the Extrapolation of Results from Clinical Studies Conducted Outside the EU to the EU-Population. EMEA/CHMP/EWP/692702/2008. Published 2008 (accessed 24.01.13). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500013468.pdf.
5. CHMP, 2010 Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia. EMA/CHMP/40072/2010 Rev. 1. Published 2010 (accessed 24.01.13). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf.
6. Ciliberto N., Bossie C.A., Urioste R., Lasser R.A. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int. Clin. Psychopharmacol. 2005, 20:207-212.
7. Cohen J. Statistical power analysis for the behavioral sciences 1988, Erlbaum, Hilllsdale (NJ). 2nd ed.
8. Cohen C.I., Cohen G.D., Blank K., Gaitz C., Katz I.R., Leuchter A., Maletta G., Meyers B., Sakauye K., Shamoian C. Schizophrenia and older adults. An overview: directions for research and policy. Am. J. Geriatr. Psychiatry 2000, 8:19-28.
9. Davies G., Welham J., Chant D., Torrey E.F., McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr. Bull. 2003, 29:587-593.
10. ICH, 1995. Topic E5. Ethnic Factors in the Acceptability of Foreign Clinical Data. CHMP/ICH/289/95. Published 1995 (accessed 24.01.13). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf.
11. ICH, 1998. Topic E8 General Considerations for Clinical Trials. CPMP/ICH/291/95. Published 1998 (accessed 24.01.13). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002877.pdf.
12. ICH, 2001. Topic E10. Choice of Control Group in Clinical Trials. CPMP/ICH/364/96. Published 2001 (accessed 24.01.13). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf.
13. Kay S.R., Fiszbein A., Lewis A.O. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
14. Khin N.A., Chen Y.F., Yang Y., Yang P., Laughren T.P. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J. Clin Psychiatry 2012, 73:856-864.
15. Krabbendam L., van Os J. Schizophrenia and urbanicity; a major environmental influence-conditional on genetic risk. Schizophr. Bull. 2005, 4:795-799.
16. March D., Hatch S.L., Morgan C., Kirkbride J.B., Bresnahan M., Fearon P., Susser E. Psychosis and place. Epidemiol. Rev. 2008, 30:84-100.
17. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence and mortality. Epidemiol. Rev. 2008, 30:67-76.
18. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
19. Pedersen C.B., Mortensen P.B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch. Gen. Psychiatry 2001, 58:1039.
20. Rado J., Janicak P.G. Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs Aging 2012, 29:783-791.
21. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005, 365:82-93.
22. Rothwell P.M. Factors that can affect the external validity of randomised controlled trials. PLoS Clin. Trials 2006, 1:e9.
23. Stauffer V.L., Sniadecki J.L., Piezer K.W., Gatz J., Kollack-Walker S., Hoffmann V.P., Conley R., Durell T. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry 2010, 3(10):89.
24. Suzuki T., Remington G., Uchida H., Rajji T.K., Graff-Guerrero A., Mamo D.C. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging 2011, 28:961-980.
25. Teo C., Borlido C., Kennedy J.L., De Luca V. The role of ethnicity in treatment refractory schizophrenia. Compr. Psychiatry 2013, 54:167-172.
26. Thiers F.A., Sinskey A.J., Berndt E.R. Trends in the globalization of clinical trials. Nat. Rev. Drug Discov. 2008, 7:13-14.
27. US Department of Health and Human Services, 2013a. Code of Federal Regulations, Title 21-Food and Drugs, Part 312, Investigational New Drug Applications, 21 CFR 312.120. Foreign Clinical Studies Not Conducted Under an IND. Updated January 4 (accessed 24.01.13). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=312.
28. US Department of Health and Human Services, 2013b. Code of Federal Regulations, Title 21-Food and Drugs, Part 314, Applications for FDA Approval to Market a New Drug, 21 CFR 314.106. Foreign Data. Updated January 4 (accessed 24.01.13). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=314.